| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/11/2005 | WO2005072669A1 Cover material and plaster with cover material |
| 08/11/2005 | WO2005072536A1 Liquid supplement compositions comprising one or more medicaments |
| 08/11/2005 | WO2005072397A2 Gastrointestinal-specific multiple drug release system |
| 08/11/2005 | WO2005072343A2 Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use |
| 08/11/2005 | WO2005072268A2 Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors |
| 08/11/2005 | WO2005072223A2 Engineered proteins, and methods of making and using |
| 08/11/2005 | WO2005072125A2 Composite materials for controlled release of water soluble products |
| 08/11/2005 | WO2005072088A2 Immunotherapy compositions, method of making and method of use thereof |
| 08/11/2005 | WO2005072079A2 Drug coating providing high drug loading and methods for providing the same |
| 08/11/2005 | WO2005072064A2 A preparation, process and a regenerative method and technioue for prevention, treatment and glycemic control of diabetes melletus |
| 08/11/2005 | WO2005063219A3 Ibuprofen-containing soft gelatin capsules |
| 08/11/2005 | WO2005060983A9 Fluidizing bed processing garlic to reduce digestive after odors |
| 08/11/2005 | WO2005055984B1 Method for preparation of salt aerosol with predefined concentration |
| 08/11/2005 | WO2005055982A3 An aqueous dispersion of hydrogel nanoparticles with inverse thermoreversible gelation |
| 08/11/2005 | WO2005055981A3 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 08/11/2005 | WO2005055973A3 Endoparasiticidal agents for topical application |
| 08/11/2005 | WO2005053617A3 Compositions and methods comprising collagen |
| 08/11/2005 | WO2005051902A8 Modified mscl protein channel |
| 08/11/2005 | WO2005051325A3 Carvedilol compositions methods of treatment and delivery |
| 08/11/2005 | WO2005049647A3 Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| 08/11/2005 | WO2005042023B1 Composite material comprising a porous semiconductor impregnated with an organic substance |
| 08/11/2005 | WO2005041876A3 Spill resistant formulations containing clays |
| 08/11/2005 | WO2005041871A3 Apparatus and method for enhancing transdermal drug delivery |
| 08/11/2005 | WO2005037245A3 A multiple route medication for the treatment of rhinitis and asthma |
| 08/11/2005 | WO2005034908A3 A solid dosage form comprising a fibrate and a statin |
| 08/11/2005 | WO2005025536A9 Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
| 08/11/2005 | WO2005012356A3 Gelatin capsules |
| 08/11/2005 | WO2005011651A3 Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| 08/11/2005 | WO2005009409A3 Controlled release preparations |
| 08/11/2005 | WO2005000283A3 A method of treating degenerative disc disease |
| 08/11/2005 | WO2004112837A8 PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR |
| 08/11/2005 | WO2004101758A3 Composition for maintaining organ and cell viability |
| 08/11/2005 | WO2004069095A3 Remote multi-purpose user interface for a healthcare system |
| 08/11/2005 | WO2004043407A3 Methods and products for treating staphylococcal infections |
| 08/11/2005 | WO2004028457A3 PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY |
| 08/11/2005 | US20050177136 Externally disposed pump for use with an internally mounted and compliant catheter |
| 08/11/2005 | US20050177106 Medical device for delivering patches |
| 08/11/2005 | US20050176993 Urokinase inhibitors, production and use thereof |
| 08/11/2005 | US20050176871 Thermoplastic Elastomer-Based Solid Emulsions |
| 08/11/2005 | US20050176829 long-term continuous administration of low doses of thyroid hormones T3(triiodothyronine ); normalization of the cellular and serum levels of T3; side effect reduction |
| 08/11/2005 | US20050176790 Pharmaceutical salts |
| 08/11/2005 | US20050176782 Medicament and method for treating vulodynia |
| 08/11/2005 | US20050176765 For therapy of glaucoma, dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia; -[1-[1-(3-Thienoyl)piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one |
| 08/11/2005 | US20050176685 Administering bisphosphonate compounds such as ibandronate, minodronate, pamidronate, risedronate, zoledronate, and alendronate; osteoporosis |
| 08/11/2005 | US20050176679 Process for the preparation of free flowing pulverized adsorbates of tibolone |
| 08/11/2005 | US20050176672 Use of cationic lipids to generate anti-tumor immunity |
| 08/11/2005 | US20050176661 Antiviral oligonucleotides |
| 08/11/2005 | US20050176657 Anthelmintic oral homogeneous veterinary pastes |
| 08/11/2005 | US20050176650 ethylenediaminetetraacetic acid (EDTA) or salt as first stabilizer, and monothioglycerol (MTG) or glutathione as second stabilizer; psychosis, agitation, pain, migraine headache, nausea, vomiting, itching, hypertension, benign prostatic hypertrophy, excess gastrointestinal secretions, sleeplessness |
| 08/11/2005 | US20050176623 Non-invasive treatment of disease using amphipathic compounds |
| 08/11/2005 | US20050176621 Crystalline compositions for controlling blood glucose |
| 08/11/2005 | US20050176619 N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl]formamide, or a pharmaceutically acceptable acid-addition salt thereof, and to the method of use thereof in the treatment of tumors and cancers. |
| 08/11/2005 | US20050176128 Method for assembling subunits into capsoids |
| 08/11/2005 | US20050175991 Using fluid comprising bacteria lysing virus bacteria as tool in cleaning fruits and vegatables |
| 08/11/2005 | US20050175959 System for the controlled delivery of an active material to a dental site |
| 08/11/2005 | US20050175814 laminate of first and second substrates fused together at certain portions so that the unfused portions form pockets that contain the functional material such as activated carbon that absorb odors, impart comfort |
| 08/11/2005 | US20050175763 Phosphatidyl serine, phosphatidyl choline and similar compounds; food for tube feeding; health-giving, performance-enhancing or disease-preventing (eg diabetes) |
| 08/11/2005 | US20050175748 Antimicrobial envelopes |
| 08/11/2005 | US20050175724 Composition for modulating at least one physiological reaction or inducing an immune response in human or animal after oral administration; for intestinal delivery of a physiologically active agent, a neutralizing agent, an inhibitor of digestive enzymes, an uptake increasing agent; synergistic |
| 08/11/2005 | US20050175713 Bismuth subnitrate in gel of aluminum stearate for sealing teat canal; mastitis |
| 08/11/2005 | US20050175710 For transfection into cells in vitro or in vivo |
| 08/11/2005 | US20050175709 Therapeutic microparticles |
| 08/11/2005 | US20050175708 For sustained release of anti-Vascular Endothelial Growth Factor aptamer to the eye |
| 08/11/2005 | US20050175707 Agitating drug in solution using low-frequency sonication, then evaporating |
| 08/11/2005 | US20050175706 Sustained release oral formulations |
| 08/11/2005 | US20050175704 Polyacrylamide hydrogel as a soft tissue filler endoprosthesis |
| 08/11/2005 | US20050175703 Polymer compositions and methods for their use |
| 08/11/2005 | US20050175702 Contains magnetic and/or metallic colloids; produced by suspension polymerization |
| 08/11/2005 | US20050175701 Prevents backflow; controlled release |
| 08/11/2005 | US20050175700 Erodable coating around core; for sustained release of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 08/11/2005 | US20050175699 Multilamellar system for the administration of active agents by means of ingestion |
| 08/11/2005 | US20050175698 Treating depression and reducing gastrointestinal side-effects; sustained release |
| 08/11/2005 | US20050175697 For use with low soluble/low dissolution rate pharmaceuticals |
| 08/11/2005 | US20050175696 Granule substrate comprising a solubilizing agent and/or a low solubility therapeutic drug, and a granule coating of a hydrophilic polymer such as methyl cellulose; oral dosage form of topiramate, comprising a tablet core and an osmotic delivery system |
| 08/11/2005 | US20050175695 exhibit biphasic plasma profile with a first plasma concentration peak level within within 14 hours of ingestion and a second plasma concentration peak level within 5-10 hours after ingestion; treats hypertension, congestive heart failure, atherosclerosis, and angina |
| 08/11/2005 | US20050175694 Long acting compositions comprising zidovudine and lamivudine |
| 08/11/2005 | US20050175693 mixture of protein and sulfated polysaccharide encapsulated with hydrophobic material; treating a disease without frequent injections; e.g. protein drug such as human serum albumin, human growth hormone, interferon-alpha, erythropoietin, and a colony stimulating factor |
| 08/11/2005 | US20050175692 Pharmaceutical formulation comprising melatonin |
| 08/11/2005 | US20050175691 Pramipexole once-daily dosage form |
| 08/11/2005 | US20050175690 Novel drug compositions and dosage forms |
| 08/11/2005 | US20050175689 Quick-disintegrating oral tablets with taste-masked drug; microparticles coated with a film of pH-independent water-insoluble polymer such as ethyl cellulose and a pH-independent water-soluble substance such as hydroxypropyl cellulose |
| 08/11/2005 | US20050175688 Fibrotic condition with associated chronic pain such as cirrhosis of the liver, atherosclerosis, dermatomyositis, progressive systemic sclerosis, pulmonary fibrosis, connective tissue diseases, adhesions and endometriosis |
| 08/11/2005 | US20050175687 Pharmaceutical formulations |
| 08/11/2005 | US20050175686 Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
| 08/11/2005 | US20050175685 uniform cylindrical form and made of an edible animal-attractive material, closed at one end and open at an opposing end, solid medication has a girth of such size as to be secured within the capsule by wedging action against the interior wall surface of the capsule |
| 08/11/2005 | US20050175684 Targeted iron chelator delivery system |
| 08/11/2005 | US20050175683 Preparation of lipid particles |
| 08/11/2005 | US20050175682 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 08/11/2005 | US20050175681 Liposomal vitamin a and method of preparation |
| 08/11/2005 | US20050175680 Transdermal delivery rate control using amorphous pharmaceutical compositions |
| 08/11/2005 | US20050175679 Controlled release formulations |
| 08/11/2005 | US20050175678 Device for the transdermal administration of a rotigotine base |
| 08/11/2005 | US20050175677 Lotion applicator |
| 08/11/2005 | US20050175676 Patch |
| 08/11/2005 | US20050175675 Film-shaped, dissolvable preparations for active substance release and method for the production thereof |
| 08/11/2005 | US20050175670 Etching semiconductor oxide layer; forming thin layers of polylactic acid; laminating substrates to face each other; masking; non-invasive drug delivery system made of biodegradable material slowly releasing a medicament for a prolonged period in a stable manner while embedded within a portion of body |
| 08/11/2005 | US20050175669 Highly lubricious hydrophilic coating utilizing dendrimers |
| 08/11/2005 | US20050175668 Lapachone delivery systems, compositions and uses related thereto |
| 08/11/2005 | US20050175665 In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration |
| 08/11/2005 | US20050175664 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors |